{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:56:49Z","timestamp":1775588209941,"version":"3.50.1"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0230869","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T20:05:16Z","timestamp":1585339516000},"page":"e0230869","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7530-8892","authenticated-orcid":true,"given":"Ferras","family":"Alashkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Rottinghaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Vance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00f6rte","family":"Herich-Terh\u00fcrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Assert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"R\u00f6th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"issue":"2","key":"pone.0230869.ref001","first-page":"205","article-title":"Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.","volume":"2","author":"A. M. Risitano","year":"2008","journal-title":"Biologics"},{"issue":"1","key":"pone.0230869.ref002","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria.","volume":"3","author":"A. Hill","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"18","key":"pone.0230869.ref003","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria.","volume":"124","author":"R. A. Brodsky","year":"2014","journal-title":"Blood"},{"issue":"10","key":"pone.0230869.ref004","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1172\/JCI77984","article-title":"The mutational landscape of paroxysmal nocturnal hemoglobinuria revealed: new insights into clonal dominance.","volume":"124","author":"S. C.-W. Lee","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"12","key":"pone.0230869.ref005","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"P. Hillmen","year":"2007","journal-title":"Blood"},{"issue":"6","key":"pone.0230869.ref006","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.","volume":"350","author":"P. Hillmen","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"pone.0230869.ref007","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.","volume":"111","author":"R. A. Brodsky","year":"2008","journal-title":"Blood"},{"issue":"12","key":"pone.0230869.ref008","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","volume":"355","author":"P. Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"pone.0230869.ref009","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"M. Loschi","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"4","key":"pone.0230869.ref010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.","volume":"95","author":"A. Hill","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"pone.0230869.ref011","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor\u2013experienced adult patients with PNH: the 302 study","volume":"133","author":"A. G. Kulasekararaj","year":"2019","journal-title":"Blood"},{"issue":"6","key":"pone.0230869.ref012","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"J. W. Lee","year":"2019","journal-title":"Blood"},{"key":"pone.0230869.ref013","unstructured":"CHMP, \u201cCommittee for Medicinal Products for Human Use (CHMP),\u201d 2019."},{"issue":"5","key":"pone.0230869.ref014","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.","volume":"125","author":"R. Peffault de Latour","year":"2015","journal-title":"Blood"},{"issue":"2","key":"pone.0230869.ref015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1248\/bpb.b15-00703","article-title":"Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"39","author":"H. Nakayama","year":"2016","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"pone.0230869.ref016","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.","volume":"162","author":"P. Hillmen","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"4","key":"pone.0230869.ref017","doi-asserted-by":"crossref","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action","volume":"13","author":"D. Sheridan","year":"2018","journal-title":"PLoS One"},{"key":"pone.0230869.ref018","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-609107-6.50022-2","article-title":"Determination of Serum Albumin","volume":"7","author":"B. T. DOUMAS","year":"1972","journal-title":"Stand. Methods Clin. Chem."},{"key":"pone.0230869.ref019","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/ajcp\/16.3_ts.40","article-title":"An accurate and rapid method for the determination of proteins in small amounts of blood serum and plasma.","volume":"10","author":"T. E. WEICHSELBAUM","year":"1946","journal-title":"Am. J. Clin. Pathol."},{"key":"pone.0230869.ref020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/clinchem\/9.4.391","article-title":"SERUM LACTIC DEHYDROGENASE ACTIVITY: AN ANALYTICAL ASSESSMENT OF CURRENT ASSAYS.","volume":"12","author":"E. AMADOR","year":"1963","journal-title":"Clin. Chem."},{"issue":"17","key":"pone.0230869.ref021","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","article-title":"Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies","volume":"2","author":"A. R\u00f6th","year":"2018","journal-title":"Blood Adv."},{"issue":"11","key":"pone.0230869.ref022","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.biocel.2009.04.005","article-title":"Complement component 5a (C5a)","volume":"41","author":"H. D. Manthey","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"pone.0230869.ref023","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/asheducation-2008.1.116","article-title":"The role of complement inhibition in PNH.","volume":"2008","author":"P. Hillmen","year":"2008","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"issue":"7","key":"pone.0230869.ref024","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/eji.1830150718","article-title":"Isolation and characterization of an Fc receptor from neonatal rat small intestine","volume":"15","author":"N. E. Simister","year":"1985","journal-title":"Eur. J. Immunol."},{"issue":"7473","key":"pone.0230869.ref025","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(66)92190-8","article-title":"The transmission of immunity from mother to young and the catabolism of immunoglobulins.","volume":"2","author":"F. W. Brambell","year":"1966","journal-title":"Lancet (London, England)"},{"issue":"10","key":"pone.0230869.ref026","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.","volume":"194","author":"M. Pyzik","year":"2015","journal-title":"J. Immunol."},{"issue":"7","key":"pone.0230869.ref027","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs","volume":"170","author":"D. C. Roopenian","year":"2003","journal-title":"J. Immunol."},{"key":"pone.0230869.ref028","unstructured":"R. Kontermann, Therapeutic proteins: strategies to modulate their plasma half-lives."},{"issue":"5","key":"pone.0230869.ref029","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1084\/jem.118.5.845","article-title":"FACTORS CONTROLLING SERUM GAMMA-GLOBULIN CONCENTRATION.","volume":"118","author":"J. L. FAHEY","year":"1963","journal-title":"J. Exp. Med."},{"key":"pone.0230869.ref030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01540","article-title":"The Neonatal Fc Receptor (FcRn): A Misnomer?","volume":"10","author":"M. Pyzik","year":"2019","journal-title":"Front. Immunol."},{"issue":"21","key":"pone.0230869.ref031","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.4996.4996","article-title":"Theraputic Monoclonal Antibody Interference In Immunofixation Electrophoresis","volume":"116","author":"E. A. Guancial","year":"2010","journal-title":"Blood"},{"issue":"6","key":"pone.0230869.ref032","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12185-011-0867-y","article-title":"Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena","volume":"93","author":"A. R\u00f6th","year":"2011","journal-title":"Int. J. Hematol."},{"key":"pone.0230869.ref033","unstructured":"A. S. Faqi, A comprehensive guide to toxicology in nonclinical drug development."},{"issue":"7","key":"pone.0230869.ref034","doi-asserted-by":"crossref","first-page":"ajt.15366","DOI":"10.1111\/ajt.15366","article-title":"The neonatal Fc receptor: Key to homeostasic control of IgG and IgG\u2010related biopharmaceuticals","volume":"19","author":"W. M. Baldwin","year":"2019","journal-title":"Am. J. Transplant."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0230869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T20:05:32Z","timestamp":1585339532000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0230869"}},"subtitle":[],"editor":[{"given":"David","family":"Dingli","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0230869","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,27]]}}}